Business Context and Reporting Period
Company: Compugen Ltd.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2002
Business Overview: Compugen is an Israeli drug and diagnostic discovery company that integrates mathematics, computer science, and physics into biology, chemistry, and medicine. Its core activities include developing computational platforms (e.g., LEADS, Genecarta) for genomic analysis and conducting in-house discovery of therapeutic proteins and diagnostic markers.
Key Financial Metrics
| Metric (in thousands USD) | 2002 | 2001 |
|---|---|---|
| Total Revenues | $11,097 | $11,360 |
| Net Loss | $(12,204) | $(15,144) |
| Operating Loss | $(15,044) | $(19,019) |
| Research & Development Expenses | $14,170 | $15,976 |
| Cash and Cash Equivalents | $5,289 | $8,438 |
| Total Cash, Deposits & Marketable Securities | $67,342 | $94,648 |
| Accumulated Deficit | $(80,592) | $(68,388) |
| Net Loss Per Share (Basic & Diluted) | $(0.47) | $(0.58) |
Liquidity: As of December 31, 2002, the company held approximately $67.3 million in cash, cash equivalents, short-term deposits, and marketable securities. Management believes these resources are sufficient to fund operations for at least the next two years.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues decreased 2% to $11.1 million in 2002 from $11.4 million in 2001. Product revenues fell 15% due to decreased sales of Bioccelerator systems, LEADS, and Genecarta, partially offset by increased OligoLibraries sales. Service revenues declined 5%.
- Grant Revenue Increase: Research and development grants increased 85% to $1.8 million, driven by increased funding from the Office of the Chief Scientist of Israel.
- Expense Reduction: Operating expenses decreased 14% to $26.1 million. R&D expenses dropped 11% and Sales & Marketing expenses dropped 16%, largely attributed to the devaluation of the Israeli Shekel against the U.S. dollar and reduced stock-based compensation amortization.
- Improved Loss Position: Net loss improved by 19% to $12.2 million, and net loss per share improved to $(0.47) from $(0.58).
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management expects to continue incurring net losses and negative cash flows in the future due to high R&D expenses. The company anticipates needing to generate significantly higher revenues to achieve profitability. No specific financial guidance for 2003 was provided, though cash reserves are projected to last at least two years.
Key Risks and Contingencies
- Profitability Risk: The company has a history of losses and may never achieve or sustain profitability.
- Customer Concentration: A small number of customers account for a large portion of revenues. In 2002, Pfizer (14%), Novartis (18%), and diaDexus (12%) represented 44% of product and service revenues.
- Technology Acceptance: The company's novel approach to drug discovery may not be accepted by customers or proven effective.
- Geopolitical Risk: Operations are based in Israel; political instability or conflict in the Middle East could disrupt operations or affect the ability to raise capital.
- Intellectual Property: Risks include the inability to patent discoveries, infringement claims from third parties, or competitors developing superior technologies.
- PFIC Status: There is a significant risk that the company may be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes due to its substantial cash position relative to its market capitalization.
Unusual Items
- Evogene Spin-off: In January 2002, the company spun off its agricultural biotechnology division into a majority-owned subsidiary, Evogene Ltd. In early 2003, Compugen forgave a $900,000 loan to Evogene in connection with a new financing round by Evogene.
- Legal Proceedings: The company received inquiries regarding potential trademark infringement (Microsoft/Genecarta) and patent infringement (Oxford Gene Technology, Carnegie Institution). No material litigation was pending as of the filing date.
Investor Verification Checklist
- Cash Burn Rate: Verify the sustainability of the $67.3 million cash position against the projected $12+ million annual net loss and R&D spend.
- Customer Renewals: Confirm the status of contracts with major customers (Pfizer, Novartis, diaDexus), as several agreements expired or were nearing expiration in early 2003.
- Grant Dependency: Assess the sustainability of the 85% increase in government grants and the conditions attached to them (e.g., manufacturing in Israel).
- PFIC Classification: Consult tax advisors regarding the potential PFIC status and its impact on U.S. shareholders' tax liabilities.
- Discovery Pipeline: Evaluate the commercial viability of the two new licensing agreements (DPC for prostate cancer diagnostics and MGVS for cardiovascular therapy) announced in 2003.